Climb Bio News and Activities

Climb Bio is a company listed under the stock ticker CLYM (US).

Acquisition, funding and merger involving Climb Bio.

• Eliem Therapeutics will change its company name to Climb Bio on Oct 3, 2024. (posted on October 3 2024).

View the org chart displaying its 18 main executives

Most searched biographies at Climb Bio

• Aoife Brennan, President, Chief Executive Officer and Director
• Judith Dunn, Director
• Breanna O'Reilly, Director

Popular executive movements at Climb Bio

• Andrew Levin, Director, has left the company  (posted on July 2 2026).
• Ashley Jones has joined the company as Senior Vice President, People and Workforce Strategy  (posted on October 21 2025).

Create your alert
to follow the executive moves at Climb Bio.

Climb Bio has 2,426 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• Archimed Group has acquired Esperion Therapeutics (posted on July 14 2026).
• The new name of ChemoTech is Neem’s Hill. (posted on July 14 2026).
• MindRank has just announced a $52 Million fundraising (posted on July 14 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by Climb Bio

• Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026 | Climb Bio
• Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Climb Bio
• Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates | Climb Bio
• Climb Bio to Present at Upcoming Investor Conferences | Climb Bio
• Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy | Climb Bio
• Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025 | Climb Bio
• Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer | Climb Bio
• Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN | Climb Bio
• Press Releases | Climb Bio
• Press Releases | Climb Bio
• View more press releases Close

Social media about Climb Bio

• Climb Bio on Wikipedia, Google News & Yahoo Finance
• Climb Bio on LinkedIn, X (Twitter) & YouTube